How to improve effectiveness of pegvisomant treatment in acromegalic patients
- 93 Downloads
Pegvisomant (PEGV) treatment in acromegaly patients resistant to somatostatin analogues is less effective in the real life than in clinical trials. This is a multicenter, observational, retrospective, longitudinal study. The aim was to detect characteristics which improve long-term PEGV effectiveness.
87 acromegalic patients treated with PEGV have been enrolled in seven referral Italian centres. PEGV was administered for up to 4 years, at doses up titrated until IGF-1 normalization or to ≥ 30 mg/day. The rate of patients who reached IGF-1 normalization at last visit has been calculated.
IGF-1 was normalized in 75.9% of patients after 1 year and in 89.6% at last visit. Disease control was associated with lower baseline GH, IGF-1 and IGF-1 xULN and was more frequent when baseline IGF-1 was < 2.7 × ULN (p < 0.02). PEGV dose was dependent on baseline IGF-1 > 2.7 × ULN (p < 0.05) and doses > 1.0 mg/BMI/day were administered more frequently when baseline IGF-1 was > 2.0 × ULN (p = 0.03). PEGV resistance was associated with higher BMI (p = 0.006) and was more frequent when BMI was > 30 kg/m2 (p = 0.07). There were no significant differences between patients treated with monotherapy or combined treatment. IGF-1 normalization, PEGV dose and rate of associated treatment were similar between males and females. PEGV effectiveness was independent from previous management. Diabetic patients needed higher doses of PEGV than non-diabetic ones.
PEGV effectiveness improves when up titration is appropriate. Higher PEGV doses at start and a more rapid up-titration are necessary in patients with obesity and/or IGF-1 > 2.7 × ULN.
KeywordsAcromegaly Pegvisomant IGF-1 Pituitary Resistance
This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.
Compliance with ethical standards
Conflict of interest
SP, AA, MRA, GA, AB, MCZ, LDM, EG, FM, CM and LT nothing to disclosure. SG, PM consultants for Pfizer. AG consultant for IPSEN, Novartis and Pfizer. SC consultant for Pfizer, Novartis and Italfarmaco, MR consultant for Italfarmaco.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 5.Giustina A., Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S. Acromegaly Consensus Group (2014) Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10:243–248CrossRefGoogle Scholar
- 10.Filopanti M, Barbieri AM, Mantovani G, Corbetta S, Gasco V, Ragonese M, Martini C, Bogazzi F, Colao A, Ferone D, Peri A, Pigliaru F, Angeletti G, Arosio M, Beck-Peccoz P, Lania AG, Spada A (2014) Role of UGT1A1and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients. Eur J Endocrinol 170:249–256CrossRefGoogle Scholar
- 11.van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Kołtowska-Häggström M (2012) Long-Term Safety of PEG-Visomant in Patients with Acromegaly: comprehensive Review of 1288 Subjects in ACROSTUDY. J Clin Endocrinol Metab 97:1589–1597CrossRefPubMedGoogle Scholar
- 13.Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist PEG-Visomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467–477CrossRefPubMedGoogle Scholar
- 16.Marazuela M, Lucas T, Alvarez-Escolá C, Puig-Domingo M, Garcia de la Torre N, de Miguel-Novoa P, Duran-Hervada A, Manzanares R, Luque-Ramírez M, Halperin I, Casanueva FF, Bernabeu I (2009) Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist PEG-Visomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol 160:535–542CrossRefPubMedGoogle Scholar
- 18.Cannavo S, Bogazzi F, Colao A, De Marinis L, Maffei P, Gomez R, Graziano E, Monterubbianesi M, Grottoli S, Italian Acrostudy Group (2015) Does pegvisomant treatment expertise improve control of resistant acromegaly? the Italian ACROSTUDY experience. J Endocrinol Invest 38:1099–1109CrossRefPubMedGoogle Scholar
- 19.Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737–740CrossRefPubMedGoogle Scholar
- 20.Giustina A, Barman A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S, Pituitary Society; European Neuroendocrine Association (2008) Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 3(1):820–838CrossRefGoogle Scholar
- 23.Bernabeu I, Pico A, Venegas E, Aller J, Alvarez-Escolá C, García-Arnés JA, Marazuela M, Jonsson P, Mir N, García Vargas M, Spanish ACROSTUDY Group (2016) Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY. Pituitary 19:127–137CrossRefPubMedGoogle Scholar
- 27.Colao A, Arnaldi G, Beck-Peccoz P, Cannavò S, Cozzi R, degli Uberti E, De Marinis L, De Menis E, Ferone D, Gasco V, Giustina A, Grottoli S, Lombardi G, Maffei P, Martino E, Minuto F, Pivonello R, Ghigo E (2007) Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest 30:693–699CrossRefPubMedGoogle Scholar
- 30.Bianchi A, Valentini F, Iuorio R, Poggi M, Baldelli R, Passeri M, Giampietro A, Tartaglione L, Chiloiro S, Appetecchia M, Gargiulo P, Fabbri A, Toscano V, Pontecorvi A, De Marinis L (2013) Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res 21:32–40Google Scholar
- 31.Buchfelder M, Weigel D, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Bidlingmaier M, Strasburger CJ (2009) Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Investigators of German Pegvisomant Observational Study. Eur J Endocrinol 161:27–35CrossRefPubMedGoogle Scholar